Steitz; Benedikt

Patent Applications and Registrations

Patent applications and USPTO patent grants for Steitz; Benedikt.The latest application filed is for "immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-p- hthalazin-1-one".

Company Profile

6.5.15

Steitz; Benedikt - Macclesfield GB
Steitz; Benedikt - Kallstadt DE
Steitz; Benedikt - Speyer N/A DE
STEITZ; Benedikt - Ludwigshafen DE
Steitz; Benedikt - Vevey CH

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Immediate Release Pharmaceutical Formulation Of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-p- Hthalazin-1-one App 20220249474 - Bechtold; Michael Karl ; et al.	2022-08-11
Solid pharmaceutical compositions for treating HCV Grant 11,246,866 - Sever , et al. February 15, 2	2022-02-15
Immediate Release Pharmaceutical Formulation Of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-p- Hthalazin-1-one App 20200323847 - Bechtold; Michael Karl ; et al.	2020-10-15
Solid Pharmaceutical Compositions for Treating HCV App 20200282004 - Sever; Nancy E. ; et al.	2020-09-10
Solid Pharmaceutical Compositions for Treating HCV App 20200253968 - Kind Code	2020-08-13
Immediate Release Pharmaceutical Formulation Of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-p- Hthal App 20190365751 - Bechtold; Michael Karl ; et al.	2019-12-05
Solid Pharmaceutical Compositions for Treating HCV App 20190216882 - Sever; Nancy E. ; et al.	2019-07-18
Immediate Release Pharmaceutical Formulation Of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-p- Hthalazin-1-one App 20180133216 - Bechtold; Michael Karl ; et al.	2018-05-17
Immediate Release Pharmaceutical Formulation Of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-p- Hthalazin-1-one App 20170173010 - Bechtold; Michael Karl ; et al.	2017-06-22
Solid Pharmaceutical Compositions for Treating HCV App 20160375087 - Sever; Nancy E. ; et al.	2016-12-29
Solid Pharmaceutical Compositions for Treating HCV App 20160375017 - Asmus; Katharina ; et al.	2016-12-29
Immediate Release Pharmaceutical Formulation Of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-p- Hthalazin-1-one App 20160008473 - Bechtold; Michael Karl ; et al.	2016-01-14
Delivery system for sustained release of a calcium-channel blocking agent Grant 9,060,986 - Breitenbach , et al. June 23, 2	2015-06-23
Immediate Release Pharmaceutical Formulation Of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-p- Hthalazin-1-one App 20140066447 - BECHTOLD; Michael Karl ; et al.	2014-03-06
Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-p- hthalazin-1-one Grant 8,475,842 - Bechtold , et al. July 2, 2	2013-07-02
Delivery System For Sustained Release Of A Calcium-channel Blocking Agent App 20120252851 - Breitenbach; Jorg ; et al.	2012-10-04
Magnetic, Paramagnetic And/or Superparamagnetic Nanoparticles App 20110045081 - Steitz; Benedikt ; et al.	2011-02-24
Pharmaceutical Formulation 514 App 20100098763 - Bechtold; Michael Karl ; et al.	2010-04-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.